A Phase 1 interventional study of JTT-662 and Placebo in Diabetes Mellitus, Type 2, sponsored by Akros Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-01-27.
Sponsored by Akros Pharma Inc. (part of Shionogi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,116th largest by enrollment of the 2,961 interventional ones that give a count, is one of 97 that started in 2020, is one of 384 in phase 1, and was the 2,369th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Montefiore Medical Center · Sites in United States
Ages 18–85
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,308 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 97 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,961 interventional studies, 128 across the 336 observational. Of the 2,651 that completed or were terminated, 1,166 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,308 have an industry lead sponsor. The 10 most frequent:
This study is registered under Akros Pharma Inc., one of the names counted as Shionogi. Under that name alone:
Akros Pharma Inc. is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Shionogi has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
189 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 189 to your calendar (.ics) → With an account.
Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
Drug: JTT-662
JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
Drug: JTT-662
JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
Drug: JTT-662
Placebo orally once daily from Day -1 to Day 28
Drug: Placebo
Active drug tablets containing JTT-662
Placebo tablets matching in appearance to the active drug tablets
Number of Subjects With Treatment-emergent Adverse Events
Treatment-emergent adverse event is defined as any adverse event (untoward medical experience occurring to a subject whether or not it is related to the study drug) with an onset date/time at/after the placebo dosing on Day -1.
Time frame: 6 Weeks (from Day -1 to the follow-up visit on Day 42)
Number of Stools and Type of Stools Based on Bristol Stool Chart
Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool Chart. The Bristol Stool Chart was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation while a score of 6 or 7 indicates diarrhea.
Time frame: 7 Weeks (from Day -6 to the follow-up visit on Day 42)
Trough Concentrations of JTT-662 in Plasma on Days 1, 7, 10, 14, 15, 21 and 28
Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTT-662 in the subjects randomized to JTT-662 treatment groups.
Time frame: 28 Days
Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28
Change from baseline in the AUEC0-4 (area under the observed effect-time curve from the start of breakfast until the 4 hour time point) for PPG were calculated using the corresponding Day -1 value as baseline and compared to the placebo values. Negative values represent greater reduction in PPG from baseline values compared to placebo.
Time frame: Days 1, 14 and 28
Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.
| Milestone | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo |
|---|---|---|---|---|
| Started | 9 | 9 | 10 | 9 |
| Randomized population | 9 | 9 | 10 | 9 |
| Safety population | 9 | 9 | 10 | 9 |
| Pk (pharmacokinetic) population | 9 | 9 | 10 | 0 |
| Pd (pharmacodynamic) population | 9 | 9 | 10 | 9 |
| Completed | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Noncompliant with study requirements | 0 | 0 | 1 | 0 |
Treatment-emergent adverse event is defined as any adverse event (untoward medical experience occurring to a subject whether or not it is related to the study drug) with an onset date/time at/after the placebo dosing on Day -1.
| Participants | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo | Placebo Run-in |
|---|---|---|---|---|---|
| Number of subjects with TEAEs | 4 | 7 | 10 | 6 | 3 |
| Number of subjects with no TEAEs | 5 | 2 | 0 | 3 | 34 |
Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool Chart. The Bristol Stool Chart was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation while a score of 6 or 7 indicates diarrhea.
| Number of stools | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo |
|---|---|---|---|---|
| Total Number of Stools | 491 | 550 | 815 | 599 |
| Type 1 | 15 | 3 | 9 | 4 |
| Type 2 | 31 | 12 | 11 | 17 |
| Type 3 | 41 | 21 | 18 | 102 |
| Type 4 | 226 | 173 | 119 | 329 |
| Type 5 | 63 | 117 | 106 | 97 |
| Type 6 | 73 | 94 | 242 | 25 |
| Type 7 | 42 | 130 | 310 | 25 |
Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTT-662 in the subjects randomized to JTT-662 treatment groups.
| ng/mL | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg |
|---|---|---|---|
| Day 1 | 60.2 ± 14.4 | 124 ± 36.0 | 231 ± 61.9 |
| Day 7 | 209 ± 61.5 | 518 ± 155 | 845 ± 359 |
| Day 10 | 235 ± 64.3 | 629 ± 181 | 959 ± 449 |
| Day 14 | 257 ± 97.3 | 703 ± 224 | 1130 ± 502 |
| Day 15 | 266 ± 83.7 | 689 ± 209 | 1140 ± 475 |
| Day 21 | 281 ± 100 | 787 ± 237 | 1180 ± 665 |
| Day 28 | 292 ± 103 | 786 ± 326 | 1190 ± 583 |
Change from baseline in the AUEC0-4 (area under the observed effect-time curve from the start of breakfast until the 4 hour time point) for PPG were calculated using the corresponding Day -1 value as baseline and compared to the placebo values. Negative values represent greater reduction in PPG from baseline values compared to placebo.
| mg*hr/dL | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo |
|---|---|---|---|---|
| Day 1 | -0.34 (-55.64 to 54.96) | -98.24 (-153.78 to -42.69) | -88.19 (-140.71 to -35.67) | 1.78 (-54.00 to 57.57) |
| Day 14 | -31.22 (-106.31 to 43.88) | -169.40 (-244.67 to -94.13) | -253.57 (-324.85 to -182.29) | -31.55 (-106.99 to 43.89) |
| Day 28 | -61.17 (-154.63 to 32.28) | -230.87 (-324.46 to -137.28) | -250.64 (-340.71 to -160.58) | -1.83 (-95.55 to 91.90) |
Collected over Up to 6 weeks (from Day -1 to the follow-up visit on Day 42). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JTT-662 5 mg | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| JTT-662 10 mg | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| JTT-662 20 mg | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Placebo | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Placebo Run-in | 0/37 (0%) | 0/37 (0%) | 3/37 (8.1%) |
| Event | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo | Placebo Run-in |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/9 | 5/9 | 10/10 | 1/9 | 2/37 |
| Anorectal discomfortGastrointestinal disorders | 0/9 | 1/9 | 3/10 | 0/9 | 0/37 |
| DyspepsiaGastrointestinal disorders | 0/9 | 0/9 | 2/10 | 0/9 | 0/37 |
| NauseaGastrointestinal disorders | 1/9 | 0/9 | 2/10 | 0/9 | 0/37 |
| Abdominal distensionGastrointestinal disorders | 1/9 | 1/9 | 1/10 | 0/9 | 0/37 |
| AbscessInfections and infestations | 0/9 | 0/9 | 0/10 | 1/9 | 0/37 |
| HordeolumInfections and infestations | 0/9 | 0/9 | 0/10 | 1/9 | 0/37 |
| Skin infectionInfections and infestations | 0/9 | 0/9 | 0/10 | 1/9 | 0/37 |
| Urinary tract infectionInfections and infestations | 0/9 | 1/9 | 0/10 | 0/9 | 0/37 |
| Limb injuryInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 1/9 | 0/37 |
| Age, Categorical(Participants) | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 10 | 9 | 35 |
| >=65 years | 1 | 1 | 0 | 0 | 2 |
| Sex: Female, Male(Participants) | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 4 | 6 | 4 | 2 | 16 |
| Male | 5 | 3 | 6 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 9 | 10 | 9 | 37 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | JTT-662 5 mg | JTT-662 10 mg | JTT-662 20 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 1 | 3 |
| White | 9 | 9 | 8 | 8 | 34 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in Feb 2021, 8 months.
Results were first posted in Jan 2023, 1 year 11 months after primary completion.
Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 8 months is above that.
Counting every sponsor, half of 517 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.